A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma PG Richardson,1 S Lonial,1 A Jakubowiak,2 S Jagannath,3 N Raje,4 D Avigan,5 IM Ghobrial,6 R Schlossman,6 A Mazumder,3 NC Munshi,6 D Vesole,7 R Joyce,5 D Doss,6 D Warren,6 L Lunde,6 R Lukas,6 S Kaster,4 K Shea,4 C Delaney,5 M Lauria,5 C Mitsiades,6 T Hideshima,6 R Knight,8 DL Esseltine,9 KC Anderson6 1Winship Cancer Institute, Atlanta, GA; 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3St. Vincent’s Comprehensive Cancer Center, New York, NY; 4Massachusetts General Hospital, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Dana-Farber Cancer Institute, Boston, MA; 7Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL; 8Celgene, Inc., Summit, NJ; 9Millennium: The Takeda Oncology Company, Cambridge, MA, USA